

**Tasigna**  
**Prior Authorization Request**

**Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155.** If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to [do\\_not\\_call@cvscaremark.com](mailto:do_not_call@cvscaremark.com). An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

**Patient's Name:** \_\_\_\_\_ **Date:** \_\_\_\_\_  
**Patient's ID:** \_\_\_\_\_ **Patient's Date of Birth:** \_\_\_\_\_  
**Physician's Name:** \_\_\_\_\_ **NPI#:** \_\_\_\_\_  
**Specialty:** \_\_\_\_\_ **Physician Office Fax:** \_\_\_\_\_  
**Physician Office Telephone:** \_\_\_\_\_  
**Request Initiated For:** \_\_\_\_\_

1. What is the patient's diagnosis?
  - Chronic myeloid leukemia (CML), *confirmed by detection of the Ph chromosome or BCR-ABL gene by cytogenetic and/or molecular testing*
  - Acute lymphoblastic leukemia (ALL), *confirmed by detection of the Ph chromosome or BCR-ABL gene by cytogenetic and/or molecular testing*
  - Gastrointestinal stromal tumor (GIST)
  - Other \_\_\_\_\_
2. What is the ICD-10 code? \_\_\_\_\_

**Complete the following section based on the patient's diagnosis.**

**Section A: Chronic Myeloid Leukemia (CML)**

3. Has the patient received a hematopoietic stem cell transplant (HSCT) for CML?  
*If Yes, no further questions*  Yes  No
4. What is the CML phase?
  - Chronic phase
  - Accelerated phase, *no further questions*
  - Blast phase, *no further questions*
5. Is this request for a new start or continuation of Tasigna therapy?
  - New start, *skip to #7*
  - Continuation
6. *If continuation of therapy and CML phase is chronic phase, is the patient receiving benefit from Tasigna therapy (i.e., achieved or maintained a cytogenetic or molecular response to therapy)?*  Yes  No *No further questions.*

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Tasigna SGM - 7/2017.

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. are both independent licensees of the Blue Cross and Blue Shield Association. The Blue Cross and Blue Shield Names and Symbols are registered trademarks of the Blue Cross and Blue Shield Association. © Registered trademark of CareFirst of Maryland, Inc.

7. *If new start and CML phase is chronic phase, what is the patient's risk score according to Sokal or Hasford methodology?*  
 Low  
 Intermediate, *no further questions*  
 High, *no further questions*  
 Unknown
8. Did the patient experience resistance to prior therapy with imatinib or an alternate tyrosine kinase inhibitor (TKI) (e.g., ponatinib (Iclusig<sup>®</sup>), dasatinib (Sprycel<sup>®</sup>), bosutinib (Bosulif<sup>®</sup>))?  Yes  No *If No, skip to #10*
9. Was the patient positive for the T315I mutation?  Yes  No  Unknown *No further questions*
10. Did the patient experience toxicity or intolerance to therapy with imatinib or an alternate TKI (e.g., ponatinib (Iclusig<sup>®</sup>), dasatinib (Sprycel<sup>®</sup>), bosutinib (Bosulif<sup>®</sup>))?  Yes  No

**Section B: Gastrointestinal Stromal Tumor (GIST)**

11. Did the patient experience disease progression on therapy with imatinib (Gleevec), sunitinib (Sutent), or regorafenib (Stivarga)?  Yes  No

***I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.***

X \_\_\_\_\_  
**Prescriber or Authorized Signature**

\_\_\_\_\_  
**Date (mm/dd/yy)**